These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 121847)

  • 1. [In vitro immunologic changes in 4 patients with lepromatous leprosy and 4 patients with borderline leprosy treated with Neisseria perflava for 17 to 25 months].
    Saint-André P; Ferracci C; Travi Piacentile M; Baquillon G
    Acta Leprol; 1979; (76-77):291-3. PubMed ID: 121847
    [No Abstract]   [Full Text] [Related]  

  • 2. [Present evaluation of hansenian treatment by association of chemotherapy and immunostimulation (author's transl)].
    Saint-Andre P; Louvet M; Giraudeau P; Discamps G; Schlecht B
    Med Trop (Mars); 1978; 38(3):331-49. PubMed ID: 723581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro immunologic changes in 7 patients with lepromatous leprosy and borderline leprosy treated with levamisole].
    Saint-André P; Travi Piacentile M; Baquillon G; Ferracci C
    Acta Leprol; 1979; (76-77):295-300. PubMed ID: 121848
    [No Abstract]   [Full Text] [Related]  

  • 4. [In vitro immunologic changes in 6 lepromatous leprosy or borderline leprosy patients treated with BCG alone or BCG and lepromin for 12 to 20 months, followed by BCG and antibiochemotherapy for 1 to 2 years].
    Saint-André P; Ferracci C; Baquillon G; Travi Piacentile M
    Acta Leprol; 1979; (76-77):311-4. PubMed ID: 121851
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of a synthetic extract (thymopentin) on the immune system of lepromatous leprosy patients.
    Munno I; Pellegrino NM; Fumo G; Barbieri G; Polimeno G; de Filippis V; Jirillo E
    Cytobios; 1987; 52(210-211):167-73. PubMed ID: 3123147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the immunological effects of cimetidine in patients with lepromatous leprosy.
    Brown AE; Nelson KE; Makonkawkeyoon S; Vithayasai V; Scollard DM; Bullock WE
    Int J Lepr Other Mycobact Dis; 1985 Dec; 53(4):559-64. PubMed ID: 3910745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery.
    Sridevi K; Khanna N; Chattree V; Pal PC; Haq W; Rao DN
    Int Immunopharmacol; 2003 Nov; 3(12):1589-600. PubMed ID: 14555284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy.
    Kar HK; Bhatia VN; Kumar CH; Sirumban P; Roy RG
    Indian J Lepr; 1986; 58(4):592-600. PubMed ID: 3572102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Result of studies of immunotherapy of lepromatous leprosy and borderline leprosy].
    Saint-André P; Baquillon G; Ferracci C; Ridel PR
    Acta Leprol; 1981; (84):39-55. PubMed ID: 6797222
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
    Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
    Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum proteins and immunoglobulins in leprosy.
    Gupta SC; Sinha SN; Sharma D; Bajaj AK; Bisht D; Mehrotra TN; Gupta RM
    Int J Lepr Other Mycobact Dis; 1978; 46(1):9-13. PubMed ID: 565758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inflammatory tuberculoid leprosy and borderline leprosy treated with long-acting sulfamides (fanasil). Clinical, bacteriologic and immunologic changes in vivo and in vitro followed for 18 to 36 months].
    Saint-André P; Ferraci C; Baquillon G; Travi Piacentile M
    Acta Leprol; 1979; (76-77):315-7. PubMed ID: 121852
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro activation of neutrophils by suspensions of Mycobacterium leprae.
    Goihman-Yahr M; Rodriguez-Ochoa G; Aranzazu N; Pinardi ME; de Gomez ME; Ocanto A; Convit J
    Int J Lepr Other Mycobact Dis; 1979 Dec; 47(4):570-4. PubMed ID: 122626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro immunologic changes in 4 patients with lepromatous leprosy treated for 1 year with rifampicin and sulfones and left untreated the following year].
    Saint-André P
    Acta Leprol; 1979; (76-77):301-2. PubMed ID: 121849
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of interleukin-2 production by adherent cell factors from lepromatous leprosy patients.
    Nath I; Jayaraman J; Sathish M; Bhutani LK; Sharma AK
    Clin Exp Immunol; 1984 Dec; 58(3):531-8. PubMed ID: 6334579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic responses in patients with lepromatous leprosy.
    Rea TH; Quismorio FP; Harding B; Nies KM; Di Saia PJ; Levan NE; Friou GJ
    Arch Dermatol; 1976 Jun; 112(6):791-800. PubMed ID: 1085131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Eruptions in the course of immunologic reversions in lepromatous patients treated with immunomodulating agents].
    Saint-André P; Baquillon G
    Acta Leprol; 1986; 4(2):201-3. PubMed ID: 3551456
    [No Abstract]   [Full Text] [Related]  

  • 19. Immuno-stimulatory effect of levamisole in borderline leprosy cases.
    Arora SK; Singh G; Sen PC
    Indian J Lepr; 1985; 57(1):22-6. PubMed ID: 3839822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in leprosy: a new approach.
    Chattopadhyay SP; Gupta CM
    Indian J Lepr; 1986; 58(2):233-9. PubMed ID: 3805795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.